Methylation of IL-2 promoter at birth alters the risk of asthma exacerbations during childhood
Article first published online: 17 FEB 2013
© 2012 Blackwell Publishing Ltd
Clinical & Experimental Allergy
Volume 43, Issue 3, pages 304–311, March 2013
How to Cite
Clinical & Experimental Allergy, 2013 (43) 304–311, , , , , ,
- Issue published online: 17 FEB 2013
- Article first published online: 17 FEB 2013
- Accepted manuscript online: 26 OCT 2012 03:35AM EST
- Manuscript Accepted: 27 SEP 2012
- Manuscript Revised: 4 SEP 2012
- Manuscript Received: 19 JUN 2012
Appendix S1. Supplementary methods.
Table S1. Characteristics of children with or without available cord blood.
Table S2. Number of asthma/wheeze exacerbations and hospital admissions in the first 8 years of life for each year.
Table S3. Association between methylation levels and severe exacerbation and hospital admission for asthma (multiple logistic regression analysis adjusted for gender, maternal asthma and maternal smoking).
Table S4. Mean methylation in cord blood in relation to hospital admissions for asthma/wheeze and severe asthma exacerbations after the first year of life.
Table S5. Conditional odds ratios for the change in the risk of hospital admission with a unit increase in methylation level for each age (univariate analysis).
Table S6. Conditional odds ratios for the change in the risk of severe asthma exacerbations with a unit increase in methylation level for each age (univariate analysis).
Table S7. Association between methylation levels and wheeze phenotypes Adjusted for gender, maternal asthma and maternal smoking at age * reference group non-wheezers
Table S8. Perinatal factors and methylation of CpG sites (continuous variables) B represents the effect that alters with a unit change in methylation.
Figure S1. CpG sites in IL-2 promoter in which methylation status was assessed.
Figure S2. Conditional odds ratios (95% CI) for the change in the risk of hospital admission for reasons other than asthma with a unit increase in methylation level of IL-2 Site1.
Figure S3. The proportion of children sensitised in quartiles of methylation.
Figure S4. DNA methylation and immunoproliferation of CBMCs with PHA (a) IL-2 Site1 (b) IL-2 Site7 and (c) LINE-1.
Figure S5. IL-2 Site1 methylation and mononuclear cell lymphoproliferative response at birth.
Figure S6. DNA methylation and immunoproliferation of CBMCs with Der p 1 (a) IL-2 Site1 (b) IL-2 Site7 and (c) LINE-1.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.